Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer

Thyroid, Volume 28, Issue 9, Page 1174-1179, September 2018.


https://ift.tt/2MwLrAa